Curevo Vaccine
6 known investors
Curevo Vaccine is a clinical-stage biotech company developing non-mRNA vaccines, with a lead adjuvanted subunit vaccine candidate (amezosvatein/CRV-101) for shingles and chickenpox. The company is running a Phase 2 program comparing amezosvatein head-to-head against Shingrix and plans a Phase 1 trial in immunocompromised children.
BiotechHealthtech
Investors · 6
In the news
Frequently asked questions
- What does Curevo Vaccine do?
- Curevo Vaccine is a clinical-stage biotech company developing non-mRNA vaccines, with a lead adjuvanted subunit vaccine candidate (amezosvatein/CRV-101) for shingles and chickenpox. The company is running a Phase 2 program comparing amezosvatein head-to-head against Shingrix and plans a Phase 1 trial in immunocompromised children.
- Who are Curevo Vaccine's investors?
- Curevo Vaccine's investors include Adjuvant Capital, OrbiMed, RA Capital, Sanofi Ventures, HBM Healthcare Investments, Medicxi.